Loading clinical trials...
Loading clinical trials...
Phase I/II Study of LY2090314 and Chemotherapy in Metastatic Pancreatic Cancer Patients With Metastases Amenable to Biopsy
Purpose of this phase I/II study is to test how well LY2090314 works in combination with different chemotherapies in treating participants with metastatic pancreatic cancer.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Mayo Clinic of Jacksonville
Jacksonville, Florida, United States
Mayo Clinic
Rochester, Minnesota, United States
Start Date
March 1, 2013
Primary Completion Date
June 1, 2015
Completion Date
June 1, 2015
Last Updated
January 15, 2019
13
ACTUAL participants
LY2090314
DRUG
FOLFOX
DRUG
Gemcitabine
DRUG
Nab-paclitaxel
DRUG
Lead Sponsor
Eli Lilly and Company
Collaborators
NCT04550494
NCT05053971
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions